Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 8:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,191 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Portland, Oregon Clear all
Active, not recruiting Phase 1 Interventional

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

NCT02942290
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 7, 2026, 8:56 AM EDT
Recruiting Phase 2 Interventional

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

NCT03270059
View directory record Official record
Conditions
Central Nervous System Neoplasm, Cranial Nerve Disorder, Metastatic Malignant Neoplasm in the Brain
Interventions
Ferumoxytol, Gadolinium, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
10 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 7, 2026, 8:56 AM EDT
Terminated Phase 2 Interventional

Pre-Prostatectomy Celecoxib or Placebo

NCT02840162
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Prostate Cancer
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 1 Interventional

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

NCT02117362
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
1 mg/kg GR-MD-02, 2 mg/kg GR-MD-02, 4 mg/kg GR-MD-02, 8 mg/kg GR-MD-02, Ipilimumab
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

NCT00819091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • National City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Jun 7, 2026, 8:56 AM EDT
Recruiting Not applicable Interventional

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

NCT06728774
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Cognitive Dysfunction
Interventions
Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD), Goal-focused Supportive Contact
Behavioral
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jun 7, 2026, 8:56 AM EDT
Terminated Phase 3 Interventional Results available

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

NCT01987960
View directory record Official record
Conditions
Post-traumatic Stress Disorder, PTSD
Interventions
Placebo, Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Los Angeles, California • Riverside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

NCT04603027
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Results available

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

NCT01524783
View directory record Official record
Conditions
Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
Interventions
Everolimus, Placebo, Best suportive care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Not applicable Interventional

An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery

NCT06079697
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Survey Administration
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 2 Interventional

S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia

NCT00006020
View directory record Official record
Conditions
Leukemia
Interventions
nelarabine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
107
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Jun 7, 2026, 8:56 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

NCT03414983
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 7, 2026, 8:56 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jun 7, 2026, 8:56 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

NCT05678205
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
AB-201, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jun 7, 2026, 8:56 AM EDT
Terminated Phase 3 Interventional Results available

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

NCT01609582
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
TAK-875, TAK-875 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
3,207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
218
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 215 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Results available

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

NCT01732796
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127, Faldaprevir (BI 201335)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
24
States / cities
Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jun 7, 2026, 8:56 AM EDT
Recruiting Phase 2 Interventional

Ferric Citrate and Chronic Kidney Disease in Children

NCT04741646
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Ferric Citrate, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 7, 2026, 8:56 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 7, 2026, 8:56 AM EDT
Recruiting Phase 1 Interventional

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

NCT06234605
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
HC-7366, Belzutifan
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jun 7, 2026, 8:56 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel in Treating Patients With Relapsed Prostate Cancer

NCT00482274
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Phase 2 Interventional

Evaluation of Treatment Methods for Clinically Significant Tinnitus

NCT00013390
View directory record Official record
Conditions
Tinnitus
Interventions
Tinnitus Masking, Tinnitus Retraining Therapy
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Jun 7, 2026, 8:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit

NCT00996320
View directory record Official record
Conditions
Sleep Deprivation, Depression
Interventions
Reduced work hour schedule
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Jun 7, 2026, 8:56 AM EDT